A Randomized, Open, Single-Centre, Crossed Study of the Effect of Food on the Pharmacokinetics of One Oral Dose of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Subjects
| Author | Songlin Zhu | en |
| Author | Jun Deng | en |
| Author | Qi Tang | en |
| Author | Jianfu Heng | en |
| Author | Jingjing Qu | en |
| Author | Yong Chen | en |
| Author | Xue Chen | en |
| Author | Nong Yang | en |
| Author | Xiaobao Liu | en |
| Author | Kunyan Li | en |
| Issued Date | 2020-07-31 | en |
| Abstract | The aim of the study was to study the PK of AST2818 tablets after one oral dose in healthy male subjects on an empty stomach and in a postprandial state and to evaluate the effect of food on AST2818 bioavailability. Sixteen healthy Chinese male subjects were randomly divided into two groups: a fasting-postprandial group and a postprandial-fasting group. The drug was administered once per evaluation at a dose of 80 mg, with an interval of 22 days between the two treatments. The LC-MS/MS method was used to determine the concentrations of AST2818 and its metabolite AST5902. Plasma pharmacokinetic parameters were calculated by noncompartmental analysis (NCA). WinNonlin® version 7.0 was used to analyse PK parameters, and SAS version 9.4 was used for statistical analyses. After a meal, the peak concentration of alflutinib increased by approximately 53%, and the AUC increased by approximately 32%; The peak concentration of its metabolite AST5902 decreased by approximately 20%, and the AUC decreased by approximately 8%. There was no significant change in peak time. The peak AST5902 concentration and AUC0-∞ were 27.4% and 71.4%, respectively, of that of alflutinib. None of the subjects experienced serious AEs, and both fasting and high-fat meal administration were safe. There was no statistically significant difference between groups in AEs (P = 0.102, RR = 1.40) or adverse reactions (P = 0.180, RR = 1.30). The effects of food may not need to be considered for the clinical use of alflutinib. No serious AEs occurred, and drug administration was safe and tolerable after fasting or a high-fat meal. | en |
| DOI | https://doi.org/10.22037/ijpr.2020.113112.14116 | en |
| Keyword | Alflutinib mesylate tablets | en |
| Keyword | Pharmacokinetics | en |
| Keyword | Healthy volunteers | en |
| Keyword | Bioavailability | en |
| Keyword | High-fat meal | en |
| Publisher | Brieflands | en |
| Title | A Randomized, Open, Single-Centre, Crossed Study of the Effect of Food on the Pharmacokinetics of One Oral Dose of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Subjects | en |
| Type | Original Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijpr-19-24.pdf
- Size:
- 489.88 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF